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Abstract
Background: The burden of anemia attributable to non-falciparum malarias in regions with Plasmodium co-endemicity is
poorly documented. We compared the hematological profile of patients with and without malaria in southern Papua,
Indonesia.
Methods and Findings: Clinical and laboratory data were linked for all patients presenting to a referral hospital between
April 2004 and December 2012. Data were available on patient demographics, malaria diagnosis, hemoglobin
concentration, and clinical outcome, but other potential causes of anemia could not be identified reliably. Of 922,120
patient episodes (837,989 as outpatients and 84,131 as inpatients), a total of 219,845 (23.8%) were associated with a
hemoglobin measurement, of whom 67,696 (30.8%) had malaria. Patients with P. malariae infection had the lowest
hemoglobin concentration (n= 1,608, mean= 8.93 [95% CI 8.81–9.06]), followed by those with mixed species infections
(n= 8,645, mean= 9.22 [95% CI 9.16–9.28]), P. falciparum (n= 37,554, mean= 9.47 [95% CI 9.44–9.50]), and P. vivax
(n= 19,858, mean = 9.53 [95% CI 9.49–9.57]); p-value for all comparisons ,0.001. Severe anemia (hemoglobin ,5 g/dl) was
present in 8,151 (3.7%) patients. Compared to patients without malaria, those with mixed Plasmodium infection were at
greatest risk of severe anemia (adjusted odds ratio [AOR] 3.25 [95% CI 2.99–3.54]); AORs for severe anaemia associated with
P. falciparum, P. vivax, and P. malariae were 2.11 (95% CI 2.00–2.23), 1.87 (95% CI 1.74–2.01), and 2.18 (95% CI 1.76–2.67),
respectively, p,0.001. Overall, 12.2% (95% CI 11.2%–13.3%) of severe anemia was attributable to non-falciparum infections
compared with 15.1% (95% CI 13.9%–16.3%) for P. falciparum monoinfections. Patients with severe anemia had an increased
risk of death (AOR= 5.80 [95% CI 5.17–6.50]; p,0.001). Not all patients had a hemoglobin measurement, thus limitations of
the study include the potential for selection bias, and possible residual confounding in multivariable analyses.
Conclusions: In Papua P. vivax is the dominant cause of severe anemia in early infancy, mixed P. vivax/P. falciparum
infections are associated with a greater hematological impairment than either species alone, and in adulthood P. malariae,
although rare, is associated with the lowest hemoglobin concentration. These findings highlight the public health
importance of integrated genus-wide malaria control strategies in areas of Plasmodium co-endemicity.
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Introduction
Anemia is a common manifestation of Plasmodium infection and
is responsible for substantial morbidity [1–4] as well as direct [5–7]
and indirect mortality [8–11]. Its pathogenesis is incompletely
understood. Acute falciparum malaria results in increased removal
from the circulation of parasitized and, to a greater extent, non-
parasitized red blood cells through a combination of splenic
filtration [12], schizont rupture, macrophage phagocytosis [13],
complement-mediated hemolysis [14], and increased free radical
damage [15,16]. In more chronic infections, decreased marrow
production of functional red blood cells due to the direct inhibitory
effects of parasites [17] and cytokines [13,18] along with
dysregulation of erythropoietin and iron metabolism [19] adds
to the anemia of ongoing red blood cell loss [16]. Although some
of these processes have been described in the non-falciparum
human malarias [20–23], less is known about the epidemiology
and pathogenesis of anemia due to these Plasmodium species [24–
26].
In regions of high P. falciparum endemicity, repeated infections
from an early age induce robust immunity to clinical disease and a
low risk of severe anemia beyond childhood [27]. However, much
of the malarious world has low or moderate malarial endemicity.
Outside of Africa, P. falciparum invariably co-exists with other
Plasmodium species—the most important of which is P. vivax. In
these regions, less intense parasite exposure during early life delays
the development of immunity and gives rise to the potential for
symptomatic and complicated infections at all ages.
Biological differences and interactions between P. falciparum and
the other Plasmodium species complicate analyses of the pattern and
public health impact of malarial anemia in co-endemic areas.
Plasmodium vivax infection has been shown to reduce the risk of
anemia secondary to P. falciparum malaria, possibly by providing a
degree of cross-species immunity [28–31]. However, recent
population-based studies have revealed a high risk of severe
anemia associated with P. vivax infection and mixed-species
infections suggesting that the hematological impact of the non-
falciparum malarias may have been underestimated [30,32–35].
The age-associated changes in risk of anemia in non-falciparum
and mixed-species infections and the consequences of anemia
caused by these species are largely unknown [26,33,34].
In the present study we used clinical and laboratory data from
Mitra Masyarakat Hospital in southern Papua, Indonesia, to
establish the comparative hematological profiles of patients
infected by the different Plasmodium species in a co-endemic setting.
Methods
Ethical Approval
Ethical approval for this study was obtained from the Health
Research Ethics Committees of the University of Gadjah Mada,
Indonesia, Menzies School of Health Research, Darwin, Australia,
and the Oxford Tropical Centre, Oxford, UK.
Study Site
Mimika District lies in south-central Papua, the easternmost
province of Indonesia. Its geography, climate, and demographics
have been described elsewhere [33,36,37]. In brief, censuses in
2004 and 2007 estimated the local population to be 130,000 and
170,000 people, respectively, approximately 50% of whom were
indigenous Papuans; the remaining 50% being Indonesians from
elsewhere in the archipelago [37]. Malaria transmission is limited
to lowland areas where it is associated with three mosquito vectors:
Anopheles koliensis, An. farauti, and An. punctulatus. The estimated
average annual incidence of parasitemia is 876 episodes per 1,000
people, 58% due to P. falciparum, 37% due to P. vivax, 3% due to
mixed infection, and 1.8% due to P. malariae [37]. The point
prevalence of asexual parasitemia in 2005 was estimated to be
7.5% for P. falciparum, 6.4% for P. vivax, 1.9% for mixed infection,
and 0.6% for P. malariae [37].
Until November 2008, Rumah Sakit Mitra Masyarakat
(RSMM) was the only referral hospital in the district; since 2008
RSMM treated approximately 80% of patients with malaria
attending an inpatient facility in the district. RSMM has 110 beds,
a high dependency unit, a 24-hour emergency department, and a
busy outpatients department that reviews approximately 300
patients per day, 6 days per week. Treatment is provided free of
charge to Papuans and at a cost for non-Papuans.
Laboratory and Data Collection Procedures
Protocols dictate that all patients presenting to the outpatients
department with a fever or symptoms consistent with malaria and
all inpatients, regardless of diagnosis, should have a malaria blood
film. As a result, reliance on clinical symptoms alone to make the
diagnosis of malaria is discouraged and rare. Microbiological
diagnosis of malaria is usually based on a thick film examination,
though confirmatory thin films and histidine rich protein (HRP2)-
based rapid diagnostic tests for P. falciparum (Paracheck) are also
performed in some cases. In 2004, a random selection of 1,083
positive slides was re-read by an independent expert microscopist
with more than 10 years of experience. Concordance was 90%
with 1.7% of cases reported as negative on the second reading
and 4% of monoinfections reclassified as mixed infections.
Complete blood counts are ordered according to clinical
indication and are performed using a Coulter Counter (JT
Coulter).
Every patient presenting to RSMM for the first time (regardless
of department) is assigned a unique hospital record number
(HRN). All clinical, laboratory, and pharmacy data from the first
and subsequent presentations are linked to this unique HRN.
Hospital clerks record basic demographic and administrative
information, mortality data, and the diagnoses given by the
attending doctor (classified according to the International
Classification of Diseases) for each patient presentation to
hospital. Ethnicity is recorded as the patient’s ‘‘Suku’’ (clan),
which is self-reported to the admission clerk on presentation to the
hospital. For the purposes of analyses, ethnicity was categorized as
Highland Papuan, Lowland Papuan, or non-Papuan on the basis
of the location of the clans’ village(s). Hematological results are
generated by coulter counter (JT Coulter) and collated in a
separate laboratory database. Pharmacy data are entered
manually into an electronic database by the pharmacist fulfilling
the prescription. Since data were gathered from routine hospital
surveillance informed consent was not requested from partici-
pants, however all records were anonymized to ensure patient
confidentiality.
Data Merging and Statistical Analyses
Clinical data were merged with hematology data by creating all
possible pairwise combinations for each HRN. Pairs in which the
laboratory record fell between the date of presentation and
discharge (the same day for outpatient visitations) were kept and if
more than one hemoglobin measurement was available for a single
event, the lowest was taken (Figure 1). For the purposes of these
analyses, mixed infection was defined as concomitant infection
with any combination of Plasmodium species.
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The primary outcomes in this study were the mean hemoglobin
concentration (g/dl) associated with infection by the different
Plasmodium species with comparison to patients without malaria,
presence of severe anemia (hemoglobin less than 5 g/dl), the
population attributable fraction (PAF) of severe anemia associated
with infection by the different Plasmodium species at all ages from
infancy through to adulthood, and all-cause mortality. Continuous
hemoglobin data were analysed using linear regression and binary
anemia data (such as severe anemia and death) were analysed
using logistic regression. Since some patients appeared in the
database multiple times, robust standard errors were calculated
using the Huber-White sandwich estimator.
Univariable analyses were performed for each of the following
variables: Plasmodium species (negative, P. falciparum, P. vivax, P.
malariae, P. ovale, or mixed species), sex, self-reported ethnicity
(non-Papuan, Highland Papuan, Lowland Papuan), age group (,1
year, 1 to ,5 years, 5 to ,15 years, $15 years), and year of
presentation (2004 through to 2012). All of these factors, as well as
the interaction between age and Plasmodium species, were
associated with clinically important differences in hematological
status and included in multivariable models. Department (outpa-
tient versus inpatient) and the number of presentations with
malaria in the preceding 2 months (0, 1, or 2 or more) were also
included in univariable analyses; however, both factors were
omitted from multivariable analyses since department was deemed
to be a consequence of severe disease rather than a confounder,
and the number of preceding malaria episodes would potentially
obscure the net hematological effect of Plasmodium infection.
Fractional polynomials were used to allow for the non-linear
relationship between age (as a continuous exposure) and the mean
hemoglobin and risk of severe anemia, because they make no
assumption regarding the shape of this association [38]. To
maintain stability of the fractional polynomial models infants
under 1 week of age (n=1114, 0.51%) were excluded since they
would not have had ex utero exposure to malaria. Adults over 63
years (the 99th percentile) of age (n=2,405, 1.1%) were also
excluded.
Adjusted PAFs of severe anemia associated with Plasmodium
infection were calculated for multiple age groups from infancy
through to adulthood from multivariable logistic regression models
Figure 1. Flow diagram of the merging process.
doi:10.1371/journal.pmed.1001575.g001
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using the punaf module for STATA, which derives PAFs using the
formulae provided in Greenland and Drescher [39]. No allow-
ances were made for within-patient correlation in these analyses
since the primary interest was the total hospital workload rather
than the hematological status of individuals. Due to very small
numbers, patients with P. ovale infections were excluded (n=31,
0.01%) from the multivariable models. All statistical analyses were
done in STATA version 12.1 (StataCorp).
Results
Between April 2004 and December 2012, there were 922,120
patient presentations to RSMM Hospital constituting 837,989
(90.9%) outpatient visitations and 84,131 (9.1%) inpatient admis-
sions (Table 1). The age distribution of all patient presentations
combined showed a peak in infancy and a second peak during the
late 20 s (Figure 2). Microscopically confirmed malaria was
Table 1. Distribution of clinical and laboratory data plus hematological status by clinical and demographic group.
Characteristics
Total
Clinical
Events
Total
Number
of Patients Distribution of Clinical and Laboratory Data Hematological Status
OP
Events
OP Events
with Hb (%)
IP
Events
IP Events
with Hb (%)
Mean
Hb
SD
g/dl p-Value*
Hb,5 g/dl
n (%) p-Value*
Species
Negative 753,595 135,229 695,051 107,436 (15.5) 58,544 44,713 (76.4) 10.51 2.65 3,844 (2.5) Ref
P. falciparum 89,748 44,171 73,392 22,225 (30.3) 16,356 15,329 (93.7) 9.47 2.89 2,444 (6.5) ,0.001
P. vivax 54,495 28,841 49,041 14,709 (30) 5,454 5,149 (94.4) 9.53 2.73 1,050 (5.3) ,0.001
Mixed infection 19,569 14,206 16,210 5,492 (33.9) 3,359 3,153 (93.9) 9.22 2.86 718 (8.3) ,0.001
P. malariae 4,598 4,045 4,190 1,222 (29.2) 408 386 (94.6) 8.93 2.54 95 (5.9) ,0.001
P. ovale 115 110 105 22 (21) 10 9 (90) 10.27 2.78 0 (0) —
Sex
Male 416,065 80,186 379,390 71,060 (18.7) 36,675 29,092 (79.3) 10.61 3 3,641 (3.6) Ref
Female 506,055 70,493 458,599 80,046 (17.5) 47,456 39,647 (83.5) 9.82 2.48 4,510 (3.8) 0.2
Ethnic group
Non-Papuan 149,017 44,196 136,604 23,357 (17.1) 12,413 9,429 (76) 12.16 2.52 Ref 365 (1.1) Ref
Highland Papuan 644,073 79,443 586,388 107,569 (18.3) 57,685 48,401 (83.9) 9.78 2.66 ,0.001 6,933 (4.4) ,0.001
Lowland Papuan 127,385 26,413 113,440 19,969 (17.6) 13,945 10,850 (77.8) 10.09 2.57 ,0.001 851 (2.8) ,0.001
Age
,1 year 70,221 20,068 55,359 13,187 (23.8) 14,862 6,753 (45.4) 9.59 2.36 ,0.001 636 (3.2) ,0.001
1 to ,5 years 139,033 23,596 124,985 29,827 (23.9) 14,048 11,482 (81.7) 9.27 2.31 ,0.001 2,094 (5.1) ,0.001
5 to ,15 years 107,163 23,318 100,319 19,673 (19.6) 6,844 6,306 (92.1) 9.66 2.5 ,0.001 1,217 (4.7) ,0.001
$15 years 605,588 101,728 557,250 88,389 (15.9) 48,338 44,170 (91.4) 10.66 2.88 Ref 4,198 (3.2) Ref
Number of malaria
presentations in last
2 m
0 799,988 150,448 724,429 128,954 (17.8) 75,559 60,717 (80.4) 10.32 2.77 6,789 (3.6)
1 105,205 30,570 98,054 18,907 (19.3) 7,151 6,695 (93.6) 9.42 2.52 1,110 (4.3)
2+ 16,927 6,972 15,506 3,245 (20.9) 1,421 1,327 (93.4) 8.9 2.36 252 (5.5)
Year
2004 62,985 25,864 56,227 8,405 (14.9) 6,758 4,565 (67.5) 9.03 2.64 Ref 925 (7.1) Ref
2005 88,400 30,950 78,398 16,825 (21.5) 10,002 8,615 (86.1) 9.56 2.69 ,0.001 1,114 (4.4) ,0.001
2006 96,086 34,260 86,288 12,686 (14.7) 9,798 8,292 (84.6) 9.81 2.78 ,0.001 1,034 (4.9) ,0.001
2007 106,046 36,914 95,272 13,847 (14.5) 10,774 9,176 (85.2) 9.65 2.89 ,0.001 1,478 (6.4) 0.01
2008 98,074 34,127 88,967 11,282 (12.7) 9,107 7,582 (83.3) 10.31 2.9 ,0.001 832 (4.4) ,0.001
2009 110,796 34,341 100,756 20,378 (20.2) 10,040 8,285 (82.5) 10.34 2.62 ,0.001 778 (2.7) ,0.001
2010 112,566 35,041 103,263 22,396 (21.7) 9,303 7,669 (82.4) 10.54 2.61 703 (2.3)
2011 115,683 37,055 106,640 19,483 (18.3) 9,043 7,023 (77.7) 10.7 2.6 559 (2.1)
2012 131,484 41,495 122,178 25,804 (21.1) 9,306 7,532 (80.9) 10.76 2.7 728 (2.2)
Total 922,120 105,448 837,989 151,106 (18.0) 84,131 68,739 (81.7) 10.18 2.76 — 8,151 (3.7) —
*p-Values based on univariable linear regression with correction of the variance-covariance matrix for within patient correlation.
OP, outpatient; IP, inpatient; hb, hemoglobin; Ref, reference category.
doi:10.1371/journal.pmed.1001575.t001
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diagnosed in 18.3% (168,525) of patient presentations, with P.
falciparum accounting for 53.3% of monoinfections, P. vivax for
32.3%, P. malariae 2.7%, and P. ovale 0.06%. Mixed species
infections were detected in 19,569 (11.6%) presentations, which in
18,489 (94.5%) cases were mixed P. falciparum and P. vivax infections.
The absolute number of patient presentations with malaria over
the study period peaked during the second year of life but as a
proportion of all patient presentations was highest during the early
teens (Figure 2). Plasmodium vivax infection was the dominant cause
of malaria in patients under 3 years of age in both the outpatient
and inpatient setting. Thereafter, P. falciparum was the most
common malaria parasite.
Availability of Hemoglobin Data
Overall, 219,845 (23.8%) patient presentations (made by 85,000
individuals) were matched with at least one hemoglobin measure-
ment. Of these 85,000 individuals, 40,427 (47.6%) had more than
one presentation to hospital; the number of presentations ranging
from 1 to 56 (median= 2). Excluding P. ovale (which was rare),
30.6% of malaria outpatient presentations were matched with a
hemoglobin measurement compared to 15.5% of non-malaria
presentations. The corresponding figures for patients admitted to
the wards were 93.9% and 76.4%, respectively. Patients who had a
hemoglobin measurement were slightly younger than those who
did not have a measurement, the median age being 23.0 years
versus 24.5 years in those without malaria and 15.9 years versus
18.2 years for those with malaria; p,0.001 for both comparisons.
Measurement of hemoglobin was also more common in males
compared to females (odds ratio = 1.02 [95% CI 1.01–1.03]) and
Papuans compared to non-Papuans (odds ratio = 1.13 [95% CI
1.12–1.15]); p,0.001 for both comparisons.
The mean of the minimum hemoglobin concentration recorded
for each patient presentation was 10.18 g/dl and the maximum
10.34 g/dl. The mean difference between minimum and maximum
Figure 2. Age distribution of patient presentations to hospital by malaria status (top) and Plasmodium species (bottom).
doi:10.1371/journal.pmed.1001575.g002
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hemoglobin was greatest for patients with P. falciparum (either alone
0.21 g/dl [standard deviation (SD) = 0.82] or mixed 0.24 g/dl
[SD=0.88]) compared to 0.17 g/dl (SD=0.80) in patients with P.
vivax and 0.14 g/dl (SD=0.72) in those with P. malariae; p,0.001.
In total 13.7% (30,174/219,845) of the patients with a
hemoglobin measurement had presented to hospital with malaria
within the previous 2 months, the number of malaria episodes
ranging from 1 to 6. The risk of recent malaria presentation was
greatest in patients presenting with P. vivax either alone or mixed
(20.5%, 5,840/28,503) compared to those with P. falciparum alone
(14.6%, 5,493/37,554), P. malariae (6%, 97/1,608), or those
without malaria (12.3% 18,742/152,149); p,0.0001. Recent
malaria caused by any species was most common in young
children aged 1 to 5 years old with an odds ratio of 2.29 (95% CI
2.21–2.37; p,0.0001) compared to adults (see Table 2).
Reduction in Hemoglobin Concentration Associated with
Malaria
The mean hemoglobin concentration and prevalence of severe
anemia varied significantly by Plasmodium species (Table 1). Mixed
infection and P. malariae infection were associated with particularly
poor hematological status (mean hemoglobin 9.22 g/dl and
8.93 g/dl, respectively; prevalence of severe anemia 8.3% and
5.9%, respectively) whilst the hematological statuses of patients
infected with P. vivax and P. falciparum monoinfection were less
severely impaired and broadly similar (Table 1). Highland
Papuans had a mean hemoglobin of 9.78 g/dl compared to a
mean of 10.09 g/dl in Lowland Papuans and 12.2 g/dl in non-
Papuans; p for comparisons with non-Papuans ,0.001 (Figure 3).
Adult females had significantly lower mean hemoglobin concen-
trations compared to adult males (mean difference =21.62 g/dl),
Table 2. Univariable and multivariable analyses of the risk factors for presentation with malaria in the previous 2 months
(n= 219,845).
Characteristics Univariable Analysis Multivariable Analysis
Crude OR [95% CI] p-Value AOR [95% CI] p-Value
PAF % [95%
CI]
Species
Negative Reference Reference
P. falciparum 1.48 [1.45–1.51] ,0.001 1.24 [1.21–1.27] ,0.001 2.0 [1.8–2.2]
P. vivax 1.90 [1.85–1.95] ,0.001 1.41 [1.37–1.45] ,0.001 2.2 [2.0–2.4]
P. malariae 0.49 [0.43–0.55] ,0.001 0.38 [0.34–0.44] ,0.001 ,0 [,0–,0]
Mixed species 1.93 [1.86–2.01] ,0.001 1.39 [1.33–1.44] ,0.001 0.8 [0.7–0.9]
Age group
$15 years Reference Reference
,1 year 0.93 [0.88–0.98] 0.01 0.92 [0.88–0.97] 0.003 ,0 [,0–,0]
1 to ,5 years 2.29 [2.21–2.37] ,0.001 2.09 [2.02–2.16] ,0.001 11.3 [11.1–11.6]
5 to ,15 years 1.48 [1.42–1.53] ,0.001 1.31 [1.27–1.36] ,0.001 2.8 [2.6–3.0]
Gender
Female 0.97 [0.94–1.00] 0.02 1.01 [0.99–1.04] 0.37 0.6 [0.0–1.1]
Ethnicity
Non-Papuan Reference Reference
Highland Papuan 4.15 [3.92–4.40] ,0.001 3.80 [3.58–4.03] ,0.001 60.9 [60.1–61.6]
Lowland Papuan 1.45 [1.34–1.56] ,0.001 1.38 [1.28–1.49] ,0.001 1.8 [1.6–2.0]
Yeara
2004 Reference Reference
2005 1.28 [1.20–1.35] ,0.001 1.28 [1.21–1.36] ,0.001
2006 1.22 [1.15–1.30] ,0.001 1.22 [1.15–1.30] ,0.001
2007 1.61 [1.52–1.71] ,0.001 1.61 [1.52–1.71] ,0.001
2008 1.58 [1.49–1.68] ,0.001 1.61 [1.52–1.71] ,0.001
2009 1.91 [1.80–2.02] ,0.001 1.79 [1.69–1.90] ,0.001
2010 1.78 [1.67–1.88] ,0.001 1.65 [1.56–1.75] ,0.001
2011 1.46 [1.38–1.55] ,0.001 1.39 [1.31–1.48] ,0.001
2012 1.99 [1.88–2.11] ,0.001 1.92 [1.82–2.04] ,0.001
Departmentb
Outpatient Reference
Inpatient 0.72 [0.71–0.74] ,0.001
aIncluded in model for calculation of overall PAFs but PAFs not presented.
bNot included in the multivariable model as deemed to be a consequence of severe disease rather than a confounder.
OR, odds ratio.
doi:10.1371/journal.pmed.1001575.t002
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and this remained apparent after excluding women known to be
pregnant (mean difference =21.46 g/dl); p,0.001.
After correcting for confounding factors, patients presenting to
hospital with malaria had lower mean hemoglobin concentrations
and higher odds of severe anemia than patients without malaria at
all ages, but most noticeably during childhood (Figure 4). Overall,
P. malariae was associated with the greatest difference in mean
hemoglobin compared to those without malaria (21.40 g/dl [95%
CI 21.52 to 21.29 g/dl]) followed by mixed infection (21.01 g/
dl [95% CI21.07 to20.95 g/dl]), P. falciparum (20.70 g/dl [95%
CI 20.73 to 20.66 g/dl]), and P. vivax (20.58 g/dl [95% CI
20.62 to 20.54 g/dl]), p for all comparisons ,0.001. Patients
without a presentation to hospital with malaria within the
preceding 2 months had a mean hemoglobin of 10.32 g/dl
(95% CI 10.30–10.33 g/dl) compared to 9.42 g/dl (95% CI 9.39–
9.45 g/dl) in patients with a single recent episode of malaria and
8.90 g/dl (95% CI 8.83–8.97 g/dl) in those with two or more
episodes of malaria; p,0.001 (Figure 5; Table 1).
The Risk of Severe Anemia
In total 97,665 (44.4%) of the 219,845 patient presentations
were associated with a hemoglobin concentration less than 10 g/
dl, 27,106 (12.3%) less than 7 g/dl, and 8,151 (3.7%) less than
5 g/dl. Compared to patients without malaria, those with mixed
Plasmodium species infections were at the greatest risk of severe
anemia (adjusted odds ratio [AOR] 3.25 [95% CI 2.99–3.54])
followed by those with P. malariae (AOR 2.18 [95% CI 1.76–2.67]),
P. falciparum (AOR 2.11 [95% CI 2.00–2.23]), and P. vivax (AOR
1.87 [95% CI 1.74–2.01]), p for all comparisons ,0.001 (Table 3).
Patients with a recent presentation to hospital with P. falciparum
malaria were at greater risk of severe anemia compared to those
with recent P. vivax infection (5.3% [783/14,743] versus to 3.7%
[459/12,507]; AOR=1.51 [95% CI 1.32–1.73]; p,0.001). The
comparative reduction in hemoglobin associated with P. malariae
was greatest in adulthood whereas for P. falciparum, P. vivax, and
mixed infections, it was worst during infancy (Figure 4).
In patients presenting to hospital the overall adjusted population
fraction of severe anemia attributable to P. falciparum was 15.1%
(95% CI 13.9–16.3%), compared to 5.75% (4.97%–6.53%) for P.
vivax, 0.61% (0.38%–0.84%) for P. malariae, and 5.89% (5.28%–
6.50%) for mixed species infections. These attributable fractions
were unchanged when pregnant women were excluded. The
fraction of severe anemia attributable to P. vivax, P. malariae, or
mixed species infections was 12.2% (95% CI 11.2%–13.3%). The
fraction of severe anemia attributable to P. vivax was highest in
infancy, when it rose to 30.4% (95% CI 26.4%–34.2%) compared
to 20.5% (95% CI 17.2%–23.7%) for P. falciparum. Following
childhood, a second peak in the fraction of anemia attributable to
malaria was apparent for all species between the ages of
approximately 15 and 25 years (Figure 6).
Figure 3. Estimated mean hemoglobin concentration in hospital attendees by ethnicity from infancy to adulthood (A) and during
the first 2 years of life (B). Figures generated by multiple fractional polynomial regression analyses with the following covariables: ethnic group by
age, Plasmodium species, sex, and year. Bands represent 95% CIs.
doi:10.1371/journal.pmed.1001575.g003
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The Consequences of Severe Anemia
Admission for inpatient care was required in 63.6% (3,166/
4,975) of the patients presenting initially to the outpatient
department with severe anemia compared to 14% (21,481/
151,454) of those without severe anemia (AOR=6.34 [95% CI
6.00–6.69], p,0.001) (Table 4). Inpatients with severe anemia had
a longer hospital stay (median 4 days [interquartile range (IQR) 2–
7 days]) compared to 3 days (IQR=2–4 days) in inpatients
without severe anemia (p,0.001).
The overall risk of mortality in those admitted to hospital with a
hemoglobin measurement was 1.3% (2,781/219,845), the risk
increasing as the hemoglobin concentration fell below 7 g/dl
(Figure 7). In total 1.5% (2,254/152,149) of patients without malaria
died compared to 0.9% (340/37,554) with P. falciparum infection,
0.6% (112/19,858) with P. vivax infection, 0.9% (0.9% 14/1,608)
with P. malariae infection, and 0.7% (61/8,645) with mixed infection.
The odds ratio for death in patients with a hemoglobin
concentration lower than 5 g/dl was 4.63 (95% CI 4.16–5.16),
compared to those with a higher hemoglobin concentration,
p,0.001. After controlling for age, the AOR of death associated
with severe anemia was 5.91 (95% CI 5.17–6.76) for patients
without concurrent malaria, 5.93 (95% CI 4.63–7.58) for those with
P. falciparum infection, 5.33 (95%CI 3.10–9.17) for mixed infections,
4.43 (95% CI 2.76–7.11) for P. vivax, and 6.58 (95% CI 2.02–21.47)
for those with P. malariae. The PAF of death associated with severe
anaemia was 11.9% (95% CI 10.6%–13.2%). The full multivariable
model for mortality is presented in Table 5.
Discussion
Anemia is highly prevalent throughout the tropics and has
major consequences for human health and socioeconomic
prosperity [40]. Our large hospital-based study in southern Papua,
Indonesia provides a comparative assessment of the pattern of
hematological changes associated with the non-falciparum malar-
ias as well as an estimate of their public health importance. We
have shown that P. vivax is associated with a high burden of severe
anemia in infancy (almost one-quarter of all cases at the hospital),
that mixed P. vivax/P. falciparum infection causes significantly more
hematological impairment than monoinfection with either species
alone, and that in adulthood P. malariae infection is associated with
the lowest mean hemoglobin concentration. Approximately 12%
of severe anemia at the hospital can be attributed to non-
falciparum Plasmodium infection, the consequences of which
include a 6-fold greater risk of admission to hospital and an
increased duration of inpatient stay. More importantly, lower
hemoglobin concentrations were associated with a 5-fold increased
risk of death, the worst prognosis being in patients with severe
anemia associated with falciparum malaria and those without
concurrent malaria.
Figure 4. Estimated mean hemoglobin in hospital attendees by Plasmodium species from infancy to adulthood (A) and during the
first 2 years of life (B) and the estimated probability of severe anemia (hemoglobin ,5 g/dl) by Plasmodium species from infancy to
adulthood (C) and during the first 2 years of life (D). Figures generated by multiple fractional polynomial regression analyses with the
following covariables: Plasmodium species by age, sex, ethnic group, and year. Bands represent 95% CIs.
doi:10.1371/journal.pmed.1001575.g004
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Infancy is a time of rapid physical and cognitive development as
well as increased vulnerability to infectious diseases. Our study shows
that the risk of symptomatic vivax malaria is more heavily skewed
towards infancy compared with other Plasmodium species, probably
reflecting more efficient transmission and faster acquisition of
immunity. For a given parasite density, P. vivax evokes a greater
immune response [41,42] than other species. Subsequent parasite
exposure is also higher due to its propensity to relapse multiple times.
In our study, patients with P. vivax infection were significantly more
likely to have had a prior presentation with malaria in the preceding
2 months compared with the other species. Infants are particularly
vulnerable to recurrent episodes of vivax malaria, a likely
consequence of lower immunity and greater inherent susceptibility
to infection; P. vivax has a strong predilection for reticulocytes, which
are most abundant in the first 3 months of life [43].
Our study confirms P. vivax as the predominant malaria infection
in infancy and highlights its frequent association with severe anemia
in this age group. Young children with severe falciparum malarial
anemia have previously been shown to have an increased risk of
mortality [5,11,40] and blood transfusion (with attendant risk of
blood borne disease transmission) [5] and they may also have
reduced resilience to other infectious and non-infectious diseases.
In our study, patients with vivax malaria and severe anemia had a
4.4-fold increase in the probability of death from any cause
compared to those without severe anaemia. However the risk of
death in those with severe anemia without concomitant malaria
and, in particular, severe anemia caused by P. falciparum infection
was much higher (Figure 5). It is possible that this is due to P.
falciparum being associated with higher parasitemia and potentially a
faster and larger decrement in hemoglobin; a rapid drop in
hemoglobin permitting less time for the body to make physiological
adjustments to ameliorate deleterious effects of severe anemia. In
contrast severe anemia caused by P. vivax infection is more likely to
be due to a chronic process, resulting from the accumulation of
smaller hemoglobin decrements with each recurrent bout of
infection. This hypothesis is supported by the greater reduction
within a single clinical encounter (maximum to minimum
hemoglobin concentration) in patients with P. falciparum (0.21 g/
dl) and mixed infections (0.24 g/dl) compared to those with P. vivax
monoinfection (0.17 g/dl), and the 1.5-fold greater risk of severe
anemia observed following recent falciparum malaria compared to
those with recent vivax malaria. In non-malarial severe anemia the
greater mortality may reflect a more acute onset compounded by a
greater number or severity of comorbidities. Our study was unable
to assess the long term effects of malarial anemia, which in other
studies has been associated with adverse developmental and
Figure 5. Estimated mean hemoglobin in hospital attendees by number of malaria episodes in the last 63 days from infancy to
adulthood (A) and during the first 2 years of life (B). 189,671 patients had no recent episodes of malaria, 30,174 had one episode, and 4,572
had two or more episodes. Figures were generated by multiple fractional polynomial regression analysis with the following covariables: number of
previous malaria episodes by age, Plasmodium species, ethnic group, sex, and year. Bands represent 95% CIs.
doi:10.1371/journal.pmed.1001575.g005
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socioeconomic sequelae, although defining these is challenging due
to the multifactorial aetiology of anemia in malaria-endemic areas
[4,11,40,44]. Malaria has been linked with impaired cognitive
development, but it is unclear if this is due to the hematological
effects of infection or the infection itself [44].
Previous studies in Thailand have shown an association between
concomitant P. vivax infection and reduced severity of P. falciparum
infection [30,31]. However this was not apparent in southern Papua
where mixed infections after 3 years of age were associated with
both a lower mean hemoglobin concentration and greater odds of
severe anemia than monoinfection with either species. This could
reflect greater antigenic diversity of local parasite strains and thus
less cross-reactive immunity, though empiric evidence for this is
lacking. Alternatively, it may relate to greater transmission intensity
in southern Papua. In this region the majority of severe malarial
anemia beyond childhood is likely to be the result of repetitive
infections in individuals who have already developed partial
immunity. In this situation, the hematological effects of the two
species are likely to be additive and any immunomodulatory effect
of P. vivax on P. falciparum is likely to be negligible. In Thailand,
Table 3. Risk factors for severe anemia (hemoglobin ,5 g/dl).
Characteristics Univariable Analysis Multivariable Analysis
Crude OR [95% CI] p-Value AOR [95% CI] p-Value Overall PAF % [95% CI]
Species
Negative Reference Reference
P. falciparum 2.69 [2.54–2.84] ,0.001 2.12 [2.00–2.25] ,0.001 15.17 [13.96–16.37]
P. vivax 2.15 [2.00–2.32] ,0.001 1.88 [1.75–2.02] ,0.001 5.79 [5.01–6.57]
P. malariae 2.42 [1.95–3.01] ,0.001 2.18 [1.75–2.71] ,0.001 0.61 [0.38–0.84]
Mixed species 3.49 [3.20–3.81] ,0.001 3.27 [2.99–3.57] ,0.001 5.90 [5.29–6.50]
Age group
$15 years Reference Reference
,1 year 1.01 [0.91–1.11] 0.89 1.05 [0.95–1.16] 0.34 0.35 [20.29 to 0.99]
1 to ,5 years 1.63 [1.52–1.75] ,0.001 1.42 [1.33–1.52] ,0.001 7.20 [5.99–8.40]
5 to ,15 years 1.50 [1.38–1.63] ,0.001 1.24 [1.14–1.35] ,0.001 2.74 [1.84–3.63]
Gender
Female 1.04 [0.98–1.10] 0.21 1.14 [1.07–1.20] ,0.001 6.25 [4.00–8.45]
Ethnicity
Non-Papuan Reference Reference
Highland Papuan 4.13 [3.66–4.66] ,0.001 3.66 [3.24–4.14] ,0.001 60.65 [57.63–63.45]
Lowland Papuan 2.52 [2.18–2.91] ,0.001 2.39 [2.07–2.77] ,0.001 5.97 [5.15–6.79]
Yeara
2004 Reference Reference
2005 0.60 [0.54–0.66] ,0.001 0.57 [0.51–0.63] ,0.001
2006 0.68 [0.61–0.75] ,0.001 0.71 [0.64–0.78] ,0.001
2007 0.89 [0.81–0.98] ,0.001 0.94 [0.85–1.03] 0.18
2008 0.60 [0.54–0.67] ,0.001 0.68 [0.61–0.75] ,0.001
2009 0.36 [0.33–0.41] ,0.001 0.36 [0.33–0.41] ,0.001
2010 0.31 [0.28–0.35] ,0.001 0.31 [0.28–0.35] ,0.001
2011 0.28 [0.25–0.32] ,0.001 0.29 [0.26–0.33] ,0.001
2012 0.29 [0.26–0.33] ,0.001 0.29 [0.26–0.32] ,0.001
Departmentb
Outpatient Reference
Inpatient 6.79 [6.44–7.16] ,0.001
Presentations with malaria in
the last 2 monthsc
No episodes Reference
1 episode 1.22 [1.14–1.31] ,0.001
2 or more episodes 1.57 [1.36–1.82] ,0.001
aIncluded in model for calculation of overall PAFs but PAFs not presented.
bNot included in the multivariable model as admission was deemed to be a consequence of severe disease rather than a confounder.
cNumber of previous presentations not included in the multivariable model as this would potentially obscure the net hematological effect of Plasmodium infection.
OR, odds ratio.
doi:10.1371/journal.pmed.1001575.t003
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where transmission is less intense, severe falciparum anemia is more
likely to result from a single fulminant infection in a non-immune
individual and therefore any immunomodulatory effect of P. vivax
would be proportionately more important.
Somewhat unexpectedly, P. malariae was found to be
associated with the lowest mean hemoglobin of all locally
prevalent Plasmodium species, and a high frequency of severe
anemia. Its hematological effects were most apparent in
adulthood whereas in childhood it was associated with minimal
impairment. Plasmodium. malariae is a slow-growing parasite that
usually causes a low parasitemia [45]. It is believed to have a
predilection for old red blood cells [45] and hence should have a
minimal effect on the average lifespan of circulating red blood
cells [46]. A high proportion of P. malariae infections is
asymptomatic and therefore unlikely to prompt presentation to
a health care service [37]. We suspect that the severity of the
hematological impairment seen in this study is related to
prolonged red cell destruction and bone marrow suppression
as a result of chronic, asymptomatic, or minimally symptomatic
parasitemia. Plasmodium malariae is prevalent in much of sub-
Saharan Africa [47] and according to the results of this study
may be associated with an underappreciated burden of anemia
in adults.
Our study has several strengths. It includes patients with
uncomplicated malaria presenting to the outpatients department
through to those with complicated disease who were admitted to
hospital. The analysis was focused on clinical events, with each
patient presenting in some cases multiple times over the 8 years of
the study period. All children greater than 1 week of age were
included whereas other studies have excluded those under 6
months of age [26]. Cases of malaria were microscopically
confirmed by quality-assured microscopists and data entry was
carried out in a consistent fashion. Because of strict hospital policy,
the vast majority of symptomatic malaria infections were likely to
have been ascertained. There are also a number of limitations to
our study. Hemoglobin measurement was done on an as-needed
basis and therefore a degree of selection bias has almost certainly
occurred. Although the majority of patients with malaria did not
have a hemoglobin measurement, the proportion of patients who
did have a measurement was the same for all species (P. ovale
excluded) and hence, comparisons of the hematological effects of
the different species are likely to be valid. Those without malaria
were less likely to have a full blood count, both in the outpatient
and inpatient setting. However, the low threshold for hematolog-
ical investigation at the hospital suggests that patients who did not
have a blood test would be unlikely to have severe anemia.
Furthermore the absence of malaria at the time of the clinical
encounter does not preclude the contribution to anemia of prior,
recently treated, asymptomatic, or submicroscopic parasitemia.
Our study was also limited to observations documented during the
hospital encounter and could not address out-of-hospital deaths
associated with severe anaemia. However these biases are likely to
have resulted in the derived malaria-attributable fractions of severe
anemia and their associated morbidity and mortality being
conservative, if anything underestimating the true burden of
disease.
Figure 6. Adjusted population attributable fractions of severe anemia (hemoglobin ,5 g/dl) by Plasmodium species and age. Figure
generated by multiple logistic regression analyses with the following covariables for each age stratum: Plasmodium species, sex, ethnic group, and
year. Bands represent 95% CIs.
doi:10.1371/journal.pmed.1001575.g006
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Our analyses may have also been subject to residual confounding.
Hemoglobin and red cell polymorphisms are known to influence the
likelihood of severe malarial anemia [48–50] and in some cases may
also modulate the risk of uncomplicated parasitemia [51–56]. We
adjusted for ethnicity, which, in Papua, is strongly indicative of the
geographic location and altitude of tribal lands and thus should have
accounted for at least some of the potential variation in the
prevalence of these disorders by malaria status.
Other potential confounders include nutritional status, geohel-
minth infestation, bacteremia, chronic disease, and pregnancy
status. Apart from pregnancy status, information on these
confounders was not available. Malaria and malnutrition may
cluster in the same geographic areas, but the mechanisms and
direction of any biological link have not been elucidated
conclusively. Chronic vivax malaria has been implicated in a
state of malnourishment akin to kwashiorkor [57], whereas iron
deficiency may provide some protection against malaria
infection [58]. Geohelminth infection causes gastrointestinal
blood loss, which may exacerbate anemia caused by P.
falciparum malaria [59]. Two oft-cited studies by Nacher and
Table 4. Univariable and multivariable analyses of the risk factors for admission to hospital from the outpatient department
(n= 156,429).
Characteristics Univariable Analysis Multivariable Analysis
Crude OR [95% CI] p-Value AOR [95% CI] p-Value PAF % [95% CI]
Anemia
Hemoglobin $5 g/dl Reference Reference
Hemoglobin ,5 g/dl 6.79 [6.44–7.16] ,0.001 6.34 [6.00–6.69] ,0.001 4.9 [4.8–5.0]
Species
Negative Reference Reference
P. falciparum 1.66 [1.62–1.70] ,0.001 1.62 [1.58–1.67] ,0.001 5.6 [5.3–5.9]
P. vivax 0.84 [0.81–0.87] ,0.001 0.86 [0.83–0.89] ,0.001 ,0 [,0–,0]
P. malariae 0.76 [0.68–0.85] ,0.001 0.73 [0.65–0.83] ,0.001 ,0 [,0–,0]
Mixed species 1.38 [1.32–1.44] ,0.001 1.50 [1.43–1.57] ,0.001 1.0 [0.9–1.1]
Age group
$15 years Reference Reference
,1 year 1.02 [0.99–1.06] 0.16 1.14 [1.10–1.18] ,0.001 0.8 [0.6–1.0]
1 to ,5 years 0.77 [0.75–0.79] ,0.001 0.76 [0.73–0.78] ,0.001 ,0 [,0–,0]
5 to ,15 years 0.64 [0.62–0.66] ,0.001 0.59 [0.57–0.61] ,0.001 ,0 [,0–,0]
Gender
Female 1.21 [1.18–1.24] ,0.001 1.19 [1.17–1.22] ,0.001 6.2 [5.6–6.9]
Ethnicity
Non-Papuan Reference Reference
Highland Papuan 1.11 [1.08–1.15] ,0.001 1.10 [1.06–1.13] ,0.001 4.1 [2.9–5.3]
Lowland Papuan 1.35 [1.29–1.40] ,0.001 1.37 [1.31–1.43] ,0.001 2.9 [2.6–3.2]
Yeara
2004 Reference Reference
2005 0.94 [0.90–0.99] 0.01 1.00 [0.96–1.05] 0.98
2006 1.20 [1.15–1.26] ,0.001 1.30 [1.24–1.36] ,0.001
2007 1.22 [1.17–1.28] ,0.001 1.27 [1.21–1.33] ,0.001
2008 1.24 [1.18–1.30] ,0.001 1.37 [1.31–1.44] ,0.001
2009 0.75 [0.72–0.78] ,0.001 0.86 [0.82–0.90] ,0.001
2010 0.63 [0.60–0.66] ,0.001 0.73 [0.69–0.76] ,0.001
2011 0.66 [0.63–0.70] ,0.001 0.77 [0.73–0.81] ,0.001
2012 0.54 [0.51–0.56] ,0.001 0.61 [0.58–0.64] ,0.001
Presentation with malaria in the last 2
monthsb
No episodes Reference
1 episode 0.75 [0.73–0.78] ,0.001
2 or more episodes 0.87 [0.81–0.93] ,0.001
aIncluded in model for calculation of overall PAFs but PAFs not presented.
bNumber of previous presentations not included in the multivariable model as this would potentially obscure the net clinical severity of Plasmodium infection.
OR, odds ratio.
doi:10.1371/journal.pmed.1001575.t004
Severe Malarial Anemia
PLOS Medicine | www.plosmedicine.org 12 December 2013 | Volume 10 | Issue 12 | e1001575
Spiegel, respectively, indicate that intestinal helminthiasis
increases the risk of falciparum malaria by a factor of 1.5
and 2.2 [60,61]. The relationship between geohelminth
infection and P. vivax malaria is unclear [62,63]. There is a
potential that the severity of anemia, and hence the attributable
fraction of anemia, associated with Plasmodium infection in our
study may have been overestimated by our inability to control
for geohelminth infection. This is unlikely to have been
important for children under 3 years old since helminth density
typically peaks in adulthood and previous work has shown
minimal impact on hemoglobin concentrations prior to 30
months of age [64].
Pregnancy may have also confounded the association of
anaemia and malaria in adults. Pregnant women are at
comparatively high risk of P. falciparum, and possibly P. vivax,
parasitemia in malaria endemic regions [65,66]. Our previous
studies at the same hospital in southern Papua have demonstrated
that primigravidae women are at increased risk of severe malarial
anemia [36]. Reassuringly in a subgroup analysis the exclusion of
women known to be pregnant did not alter the PAF of anemia
associated with malaria.
Finally the results of this study cannot necessarily be generalised
to individuals with asymptomatic disease. Although cross-sectional
survey data could be used to compare the hematological impact of
symptomatic and asymptomatic Plasmodium infection this approach
would tend to miss patients at the severe end of the spectrum.
In conclusion our very large hospital-based study demon-
strates that the non-falciparum malarias make a major contri-
bution to the burden of anemia in southern Papua, with 12% of
all severe anemia at the hospital attributable to P. vivax, P.
malariae, or mixed species infections. Plasmodium vivax was
associated with the greatest attributable fraction of severe
anemia in infancy and is likely to be an important cause of
indirect morbidity. Conversely, the hematological impact of P.
malariae was most apparent in adults. In contrast to earlier
reports from regions of low mixed-species endemicity, mixed P.
falciparum/P. vivax infections are associated with a significantly
greater absolute reduction in hemoglobin and odds of severe
anemia than monoinfection with either species alone. Severe
malarial anemia, including that caused by P. vivax infection, is
associated with an increased likelihood of admission, a prolonged
hospital stay, and, particularly with P. falciparum infections,
dramatically increased mortality. These findings highlight the
public health importance of integrated genus-wide rather than
species-specific malaria control strategies in areas of Plasmodium
co-endemicity.
Figure 7. Estimated probability of mortality by hemoglobin concentration overall (A) and by Plasmodium species (B). Figures
generated by multiple fractional polynomial regression analyses with the following covariables: Plasmodium species, hemoglobin, age, sex, ethnic
group, and year. Bands represent 95% CIs. Risk of death in Figure 6A= 1/(1+exp(2(21.4420.4146 * hb+0.0006 * hb3))), where the other covariates in
the model are set equal to their mean value (for continuous variables) or prevalence (for indicator variables).
doi:10.1371/journal.pmed.1001575.g007
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Table 5. Univariable and multivariable analyses of the risk factors for death (n= 219,845).
Characteristics Univariable Analysis Multivariable Analysis
Crude OR [95% CI] p-Value AOR [95% CI] p-Value PAF % [95% CI]
Anemia
Hemoglobin $5 g/dl Reference Reference
Hemoglobin ,5 g/dl 4.63 [4.16–5.16] ,0.001 5.80 [5.17–6.50] ,0.001 11.9 [10.6–13.2]
Species
Negative Reference Reference
P. falciparum 0.61 [0.54–0.68] ,0.001 0.57 [0.51–0.65] ,0.001 ,0 [,0–,0]
P. vivax 0.38 [0.31–0.46] ,0.001 0.37 [0.31–0.45] ,0.001 ,0 [,0–,0]
P. malariae 0.58 [0.34–0.99] 0.05 0.57 [0.34–0.98] 0.04 ,0 [,0–,0]
Mixed species 0.47 [0.37–0.61] ,0.001 0.45 [0.35–0.59] ,0.001 ,0 [,0–,0]
Age group
$15 years Reference Reference
,1 year 1.43 [1.28–1.60] ,0.001 1.40 [1.25–1.58] ,0.001 4.0 [2.5–5.4]
1 to ,5 years 0.60 [0.53–0.67] ,0.001 0.62 [0.55–0.70] ,0.001 ,0 [,0–,0]
5 to ,15 years 0.57 [0.49–0.66] ,0.001 0.60 [0.51–0.69] ,0.001 ,0 [,0–,0]
Gender
Female 0.63 [0.58–0.68] ,0.001 0.58 [0.54–0.63] ,0.001 ,0 [,0–,0]
Ethnicity
Non-Papuan Reference Reference
Highland Papuan 0.61 [0.55–0.67] ,0.001 0.64 [0.58–0.71] ,0.001 ,0 [,0–,0]
Lowland Papuan 0.93 [0.83–1.05] 0.26 0.95 [0.84–1.08] 0.46 ,0 [,0–1.4]
Yeara
2004 Reference Reference
2005 0.99 [0.81–1.21] 0.94 1.09 [0.89–1.33] 0.39
2006 1.41 [1.16–1.71] ,0.001 1.47 [1.21–1.79] ,0.001
2007 1.57 [1.30–1.89] ,0.001 1.54 [1.27–1.86] ,0.001
2008 1.85 [1.53–2.24] ,0.001 1.84 [1.52–2.23] ,0.001
2009 0.93 [0.77–1.13] 0.48 1.04 [0.85–1.27] 0.70
2010 0.77 [0.63–0.94] 0.01 0.87 [0.71–1.07] 0.19
2011 0.95 [0.78–1.16] 0.60 1.05 [0.86–1.29] 0.61
2012 0.87 [0.71–1.05] 0.15 0.99 [0.81–1.20] 0.90
Presentation with malaria in the last 2
monthsb
No episodes Reference
1 episode 0.63 [0.54–0.72] ,0.001
2 or more episodes 0.59 [0.42–0.82] ,0.001
aIncluded in model for calculation of overall PAFs but PAFs not presented.
bNumber of previous presentations not included in the multivariable model as this would potentially obscure the net clinical severity of Plasmodium infection.
OR odds ratio.
doi:10.1371/journal.pmed.1001575.t005
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Editors’ Summary
Background. Malaria—a mosquito-borne parasitic dis-
ease—is a global public health problem. Five parasites cause
malaria—Plasmodium falciparum, P. vivax, P. ovale, P.
malariae, and P. knowlesi. Of these, P. vivax is the commonest
and most widely distributed, whereas P. falciparum causes
the most deaths—about a million every year. All these
parasites enter their human host when an infected mosquito
takes a blood meal. The parasites migrate to the liver where
they replicate and mature into a parasitic form known as
merozoites. After 8–9 days, the merozoites are released from
the liver cells and invade red blood cells where they replicate
rapidly before bursting out and infecting more red blood
cells. Malaria’s recurring flu-like symptoms are caused by this
cyclical increase in parasites in the blood. Malaria needs to
be treated promptly with antimalarial drugs to prevent the
development of potentially fatal complications. Infections
with P. falciparum in particular can cause anemia (a reduction
in red blood cell numbers) and can damage the brain and
other vital organs by blocking the capillaries that supply
these organs with blood.
Why Was This Study Done? It is unclear what proportion
of anemia is attributable to non-falciparum malarias in
regions of the world where several species of malaria
parasite are always present (Plasmodium co-endemicity).
Public health officials in such regions need to know whether
non-falciparum malarias are a major cause of anemia when
designing malaria control strategies. If P. vivax, for example,
is a major cause of anemia in an area where P. vivax and P.
falciparum co-exist, then any malaria control strategies that
are implemented need to take into account the biological
differences between the parasites. In this hospital-based
cohort study, the researchers investigate the burden of
severe anemia from the endemic Plasmodium species in
southern Papua, Indonesia.
What Did the Researchers Do and Find? The researchers
used hospital record numbers to link clinical and laboratory
data for patients presenting to a referral hospital in southern
Papua over an 8-year period. The hemoglobin level (an
indicator of anemia) was measured in about a quarter of
hospital presentations (some patients attended the hospital
several times). A third of the presentations who had their
hemoglobin level determined (67,696 presentations) had
clinical malaria. Patients with P. malariae infection had the
lowest average hemoglobin concentration. Patients with
mixed species, P. falciparum, and P. vivax infections had
slightly higher average hemoglobin levels but all these levels
were below the normal range for people living in Papua.
Among the patients who had their hemoglobin status
assessed, 3.7% had severe anemia. After allowing for other
factors that alter the risk of anemia (‘‘confounding’’ factors
such as age), patients with mixed Plasmodium infection were
more than three times as likely to have severe anemia as
patients without malaria. Patients with P. falciparum, P. vivax,
or P. malariae infections were about twice as likely to have
severe anemia as patients without malaria. About 12.2% of
severe anemia was attributable to non-falciparum infections,
15.1% was attributable to P. falciparum monoinfections, and
P. vivax was the dominant cause of severe anemia in infancy.
Finally, compared to patients without anemia, patients with
severe anemia had nearly a 6-fold higher risk of death.
What Do These Findings Mean? These findings provide a
comparative assessment of the pattern of anemia associated
with non-falciparum malarias in Papua and an estimate of
the public health importance of these malarias. Although the
accuracy of these findings may be affected by residual
confounding (for example, the researchers did not consider
nutritional status when calculating how much malaria
infection increases the risk of anemia) and other limitations
of the study design, non-falciparum malarias clearly make a
major contribution to the burden of anemia in southern
Papua. In particular, these findings reveal the large contri-
bution that P. vivax makes to severe anemia in infancy, show
that the hematological (blood-related) impact of P. malariae
is most apparent in adulthood, and suggest, in contrast to
some previous reports, that mixed P. vivax/P. falciparum
infection is associated with a higher risk of severe anemia
than monoinfection with either species. These findings,
which need to be confirmed in other settings, highlight the
public health importance of implementing integrated ma-
laria control strategies that aim to control all Plasmodium
species rather than a single species in regions of Plasmodium
co-endemicity.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001575.
N This study is further discussed in a PLOS Medicine
Perspective by Gosling and Hsiang
N Information is available from the World Health Organiza-
tion on malaria (in several languages); the 2012 World
Malaria Report provides details of the current global
malaria situation
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish), including
information on different Plasmodium species and a
selection of personal stories about malaria
N The Malaria Vaccine Initiative has fact sheets on
Plasmodium falciparum malaria and on Plasmodium vivax
malaria
N MedlinePlus provides links to additional information on
malaria and on anemia (in English and Spanish)
N Information is available from the WorldWide Antimalarial
Resistance Network on antimalarial drug resistance for P.
falciparum and P. vivax
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